OmniAb (OABI) Non-Current Deffered Revenue (2021 - 2026)
OmniAb (OABI) reported Non-Current Deffered Revenue of $369000.0 for Q1 2026, up 778.57% on a QoQ basis from $42000.0 in Q2 2025.
OmniAb (OABI) has 6 years of Non-Current Deffered Revenue data on file, last reported at $369000.0 in Q1 2026.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $369000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $369000.0 (changed N/A YoY) and the FY2024 annual result came in at $117000.0, down 86.43% from the prior year.
- Non-Current Deffered Revenue improved to $369000.0 in Q1 2026 per OABI's latest filing, from $42000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $8.0 million in Q1 2022 and bottomed at $41000.0 in Q3 2024.
- The 5-year median for Non-Current Deffered Revenue is $1.4 million (2023), against an average of $2.5 million.
- The widest annual swing landed in 2024, when Non-Current Deffered Revenue slumped 97.93%; it then tumbled 41.67% in 2025.
- Tracing OABI's Non-Current Deffered Revenue over 5 years: stood at $4.3 million in 2022, then sank by 80.07% to $862000.0 in 2023, then plunged by 86.43% to $117000.0 in 2024, then slumped by 64.1% to $42000.0 in 2025, then surged by 778.57% to $369000.0 in 2026.
- Per Business Quant, the three latest OABI Non-Current Deffered Revenue figures stand at $369000.0 (Q1 2026), $42000.0 (Q2 2025), and $117000.0 (Q4 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn | 369,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 369,000.00 |
| Jun 30, 2025 | 42,000.00 |
| Dec 31, 2024 | 117,000.00 |
| Sep 30, 2024 | 41,000.00 |
| Jun 30, 2024 | 72,000.00 |
| Mar 31, 2024 | 279,000.00 |
| Dec 31, 2023 | 862,000.00 |
| Sep 30, 2023 | 1.95 Mn |
| Jun 30, 2023 | 3.48 Mn |
| Mar 31, 2023 | 3.02 Mn |
| Dec 31, 2022 | 4.33 Mn |
| Sep 30, 2022 | 4.03 Mn |
| Jun 30, 2022 | 8.05 Mn |
| Mar 31, 2022 | 8.05 Mn |
| Dec 31, 2021 | 9.23 Mn |
| Sep 30, 2021 | 8.05 Mn |